Editor's note: Nonarteritic anterior ischemic optic neuropathy (NAION), a form of optic nerve stroke, has received attention as the result of a possible rare association with PDE5 inhibitors (PDE5i). The possible mechanism of the PDE5i interaction with NAION is unclear, and the sporadic case reports do not seem to shed light on this topic. There is little guidance on this subject for the patient and clinician alike. Nonetheless, clinicians are being deluged with queries, without definitive answers. At this juncture, an ophthalmologic evaluation is discretionary, and appears to be based on either patient desire, patient risk factor profile, or clinician instinct. The scientific literature is scant as well. Several case reports exist to date, without clear vision for the future study of this disease. Robert Tomsak, a noted neuro-ophthalmologist, discusses NAION here.
PDE5 inhibitors and permanent visual loss
Recent reports of permanent visual loss associated with the use of sildenafil citrate (Viagra) and tadalafil (Cialis) have provoked an explosion of media coverage. An Internet search reveals that this topic has received worldwide attention among the lay public, health care professionals and, not unexpectedly, the legal profession, some of whom have websites soliciting potential plaintiffs for law suits. To put this issue in perspective, a few basic questions will be considered:
(1) Are PDE5 inhibitors (PDE5i) the cause of nonarteritic anterior ischemic optic neuropathy (NAION), a form of optic nerve stroke? (2) If so, by what mechanism does this occur? (3) If PDE5 use predisposes to NAION, are certain individuals at higher risk for this possible adverse drug effect, and can they be identified before a prescription is written?
Prior to answering these questions, I will discuss NAION.
Next to glaucoma, NAION is the most common acquired optic neuropathy in persons older than 50 y. It is an infarction of the optic nerve in the region where it passes through the sclera, just behind the optic disc (the part of the optic nerve that is visible with the ophthalmoscope).
The annual incidence of this disease is, at most, about 1 in 10 000. Men and women are about equally affected and it is much more common in Caucasians than in African Americans, Asians and Hispanics. Most people are in the seventh or eight decades of life when they are affected. Familial cases are extremely rare. The degree of visual acuity and visual field loss is usually significant, but most patients do not become legally blind. There is no effective treatment once vision is lost. The natural history of the visual loss is that about 60% of patients get neither better or worse over time, about 30% improve a line or two on the eye chart over a period of weeks, and about 10% progressively worsen to some degree over the same time interval, and then stabilize.
Most persons who develop NAION have 'structurally congested' optic discs. In other words, the scleral canal through which the axons pass is narrower than normal resulting in the optic nerve axons being packed more closely together. This causes the surface of the optic disc to be slightly elevated and to have a small or absent physiologic cup-we now term this appearance a 'disc at risk' for the development of NAION. Why this structural anomaly predisposes to NAION is not known, but the association of the two is incontrovertible. As both optic nerves have a similar structure and appearance in most people, it is not surprising that the fellow eye is affected sequentially by NAION at least 15% of the time months or years later.
Local atherosclerosis and arteriosclerosis of nutrient vessels in this region of the optic nerve probably are predisposing factors since most persons who develop NAION have risk factors like hypertension, diabetes, hypercholesterolemia, or a history of cigarette smoking, and these changes have been shown histologically in optic nerve vessels in the few specimens studied. What is not commonly present in NAION is widespread thrombotic or embolic occlusion of relevant optic nerve vessels, or evidence of this type of occlusion on intravenous fluorescein angiograms of the optic nerve circulation.
Another factor that is a likely precipitating factor in NAION is nocturnal hypotension. Up to 75% of patients either wake up with visual loss or note it in the morning. Dr Sohan S Hayreh (Department of Ophthalmology, University of Iowa, Iowa City, IA, USA) and others have shown a greater frequency and degree of nocturnal diastolic hypotension in patients with NAION. In some other studies, NAION has been associated with sleep apnea.
The PDE5i-NAION connection
To date there are about 50 reported cases of NAION associated with PDE5i use and less than 20 published in the medical literature (Transient blue/ green color vision disturbance due to inhibition of PDE6 will not be considered in this discussion). Of these, only two involved the use of tadalafil (Cialis) and the others involved sildenafil citrate (Viagra). All the episodes of NAION occurred in men. Optic disc morphology was documented in the majority of cases and all these had 'discs at risk'. About half had at least one risk factor for atherosclerotic cardiovascular disease. The average age of the group was about 60 y, but two patients were 42 and had no cardiovascular risk factors, but did have 'discs at risk'. The time interval between ingestion of PDE5i and visual loss ranged from minutes to a day and a half, with the most common interval being a few hours. Seven of the patients noted visual loss the following morning. There has been no clear association with amount of medication taken.
A 'StatGram' dated July 20, 2005 sent to physicians by Pfizer Labs, emphasized that an estimated 27 million men worldwide have used Viagra, and that clinical trials performed by the manufacturer involved over 13 000 men with no reports of NAION.
The most intriguing report to date involves the use of tadalafil. 
How could PDE5i result in NAION?
Effects on systemic blood pressure As noted above, nocturnal hypotension is a likely precipitating factor in the development of NAION. Review of the manufacturers' product data shows that sildenafil citrate and vardenafil HCL lower systolic and diastolic blood pressure a small, but measurable amount. The effect on patients with 'discs at risk', with or without other cardiovascular risk factors, is not known. Also, warning is given for all three PDE5i, when used with antihypertensive drugs, nitrates, and ethanol because of the possible additive hypotensive effect. Most of the published cases of visual loss do not have detailed information regarding blood pressure.
Direct negative effect on optic nerve blood flow auto regulation
Whether or not PDE5i have a direct effect on optic disc blood flow auto regulation in persons with 'discs at risk' is not known.
How should the prescriber of PDE5i 'screen' the patient for risk factors for NAION?
Given the issues discussed previously, the single most important factor to determine is: does the patient have a 'disc at risk'? The direct ophthalmoscope is a sufficient tool to determine this in most patients, but occasionally other instruments available only to eye care professionals are necessary. If a 'disc at risk' is present, then it would be prudent to obtain other information, such as:
Eye history
Ask about any significant visual problem, other than the need for glasses. This would include glaucoma, macular degeneration, diabetic retinopathy, previous eye surgery, significant eye trauma, and any other form of visual impairment, including NAION. If any of these conditions are present, it would be prudent to consult an eye care professional for an additional opinion.
General history
Every effort should be made to avoid causing, or aggravating, hypotension, by the use of a PDE5i. Therefore, asking about present antihypertensive medications, nitrates, and other drugs that alter the metabolism of PDE5i (eg erythromycin and protease 
Summary
The best evidence available indicates that NAION is caused by a drop in perfusion pressure in the prelaminar region of the optic nerve leading to ischemic infarction. The major predisposing factor is the anatomic structure of the optic nerve ('disc at risk') followed by systemic risk factors for atherosclerosis and arteriosclerosis. The use of PDE5i in persons with one or more of these risk factors may increase the chance of developing NAION. The use of PDE5i and the development of NAION remains a rare, but well documented, event that requires further study.
